Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) and Ablynx (OTCMKTS:ABLYF – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.
Risk and Volatility
Cidara Therapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Ablynx has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500.
Valuation & Earnings
This table compares Cidara Therapeutics and Ablynx’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cidara Therapeutics | $84.57 million | 0.92 | -$29.80 million | ($0.13) | -6.62 |
| Ablynx | $62.73 million | 60.74 | -$122.67 million | N/A | N/A |
Analyst Ratings
This is a summary of current recommendations for Cidara Therapeutics and Ablynx, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cidara Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| Ablynx | 0 | 0 | 0 | 0 | N/A |
Cidara Therapeutics currently has a consensus target price of $4.67, suggesting a potential upside of 442.57%. Given Cidara Therapeutics’ higher probable upside, analysts plainly believe Cidara Therapeutics is more favorable than Ablynx.
Institutional and Insider Ownership
29.1% of Cidara Therapeutics shares are held by institutional investors. 6.3% of Cidara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Cidara Therapeutics and Ablynx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cidara Therapeutics | -9.72% | -67.95% | -12.45% |
| Ablynx | N/A | N/A | N/A |
Summary
Cidara Therapeutics beats Ablynx on 6 of the 11 factors compared between the two stocks.
About Cidara Therapeutics
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
About Ablynx
Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
